Liver cancer prevention trial tests Low-Dose erlotinib
NCT ID NCT04172779
First seen Nov 20, 2025 · Last updated Apr 30, 2026 · Updated 24 times
Summary
This study tests whether a low dose of the drug erlotinib can prevent liver cancer in people with advanced liver scarring (fibrosis or cirrhosis). About 60 adults will receive either erlotinib or a placebo for a period of time. Researchers will check if the drug changes a blood test linked to liver cancer risk and monitor for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS, LIVER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.